Patient, transplant, and disease characteristics
| Characteristics . | All patients (n = 2985) . | Conditioning regimens as classified per intensity . | ||
|---|---|---|---|---|
| High dose (N = 1844) . | Reduced intensity (N = 460) . | Nonmyeloablative (N = 681) . | ||
| n (%) . | n (%) . | |||
| HCT-CI scores | ||||
| 0 | 953 (32) | 694 (38) | 102 (22) | 157 (23) |
| 1 | 437 (15) | 300 (16) | 57 (12) | 80 (12) |
| 2 | 493 (17) | 289 (16) | 72 (16) | 132 (19) |
| 3 | 531 (18) | 290 (16) | 104 (23) | 137 (20) |
| 4 | 255 (9) | 131 (7) | 53 (12) | 71 (10) |
| ≥5 | 316 (10) | 140 (7) | 72 (15) | 104 (15) |
| Age, years | ||||
| 0-19 | 410 (14) | 333 (18) | 35 (8) | 42 (6) |
| 20-39 | 760 (25) | 597 (32) | 85 (18) | 78 (11) |
| 40-49 | 684 (23) | 467 (25) | 96 (21) | 121 (18) |
| 50-59 | 765 (26) | 390 (21) | 143 (31) | 232 (34) |
| ≥60 | 366 (12) | 57 (3) | 101 (22) | 208 (31) |
| KPS | ||||
| 100% | 1104 (37) | 776 (42) | 143 (31) | 185 (27) |
| 90-95% | 1090 (37) | 655 (35) | 183 (40) | 252 (37) |
| 80-85% | 543 (18) | 310 (17) | 89 (19) | 154 (23) |
| ≤75% | 248 (8) | 103 (6) | 45 (10) | 90 (13) |
| Prior regimens | ||||
| 0 | 470 (16) | 288 (16) | 100 (22) | 82 (12) |
| 1 | 510 (17) | 380 (21) | 60 (13) | 70 (10) |
| 2 | 735 (25) | 480 (26) | 99 (22) | 156 (23) |
| 3 | 587 (20) | 368 (20) | 84 (18) | 135 (20) |
| ≥4 | 683 (23) | 328 (18) | 117 (26) | 238 (35) |
| Patient CMV serology-status* | ||||
| Positive | 1835 (61) | 1140 (62) | 286 (62) | 409 (60) |
| Negative | 1122 (38) | 690 (37) | 169 (37) | 263 (39) |
| Unknown | 28 (1) | 14 (1) | 5 (1) | 9 (1) |
| Stem cell source | ||||
| Marrow | 641 (21) | 527 (29) | 70 (15) | 44 (6) |
| PBMC | 2344 (79) | 1371 (71) | 390 (85) | 637 (94) |
| Donor | ||||
| Related | 1648 (55) | 1041 (56) | 238 (52) | 369 (54) |
| Unrelated | 1337 (45) | 803 (44) | 222 (48) | 312 (46) |
| GVHD prophylaxis regimen† | ||||
| CSP/MMF | 760 (25) | 95 (5) | 129 (28) | 536 (79) |
| CSP/MTX | 1066 (36) | 954 (52) | 89 (19) | 23 (3) |
| Tacrolimus-based | 480 (16) | 340 (18) | 68 (15) | 72 (11) |
| Triple drugs | 342 (11) | 280 (15) | 52 (11) | 10 (1) |
| Sirolimus-based | 147 (5) | 76 (4) | 70 (15) | 1 (<1) |
| Others | 38 (1) | 32 (2) | 5 (1) | 1 (<1) |
| Unknown | 152 (5) | 67 (4) | 47 (10) | 38 (6) |
| Diagnoses‡ | ||||
| Myeloid | 1802 (60) | 1241 (67) | 279 (61) | 282 (41) |
| Lymphoid | 1053 (35) | 566 (31) | 137 (30) | 348 (51) |
| Nonmalignant diseases | 130 (5) | 37 (2) | 42 (9) | 51 (8) |
| Disease risk for relapse§ | ||||
| High | 1797 (60) | 1025 (56) | 302 (66) | 470 (69) |
| Low | 1128 (38) | 789 (43) | 150 (33) | 189 (28) |
| Nonmalignant diseases | 60 (2) | 30 (2) | 8 (2) | 22 (3) |
| Characteristics . | All patients (n = 2985) . | Conditioning regimens as classified per intensity . | ||
|---|---|---|---|---|
| High dose (N = 1844) . | Reduced intensity (N = 460) . | Nonmyeloablative (N = 681) . | ||
| n (%) . | n (%) . | |||
| HCT-CI scores | ||||
| 0 | 953 (32) | 694 (38) | 102 (22) | 157 (23) |
| 1 | 437 (15) | 300 (16) | 57 (12) | 80 (12) |
| 2 | 493 (17) | 289 (16) | 72 (16) | 132 (19) |
| 3 | 531 (18) | 290 (16) | 104 (23) | 137 (20) |
| 4 | 255 (9) | 131 (7) | 53 (12) | 71 (10) |
| ≥5 | 316 (10) | 140 (7) | 72 (15) | 104 (15) |
| Age, years | ||||
| 0-19 | 410 (14) | 333 (18) | 35 (8) | 42 (6) |
| 20-39 | 760 (25) | 597 (32) | 85 (18) | 78 (11) |
| 40-49 | 684 (23) | 467 (25) | 96 (21) | 121 (18) |
| 50-59 | 765 (26) | 390 (21) | 143 (31) | 232 (34) |
| ≥60 | 366 (12) | 57 (3) | 101 (22) | 208 (31) |
| KPS | ||||
| 100% | 1104 (37) | 776 (42) | 143 (31) | 185 (27) |
| 90-95% | 1090 (37) | 655 (35) | 183 (40) | 252 (37) |
| 80-85% | 543 (18) | 310 (17) | 89 (19) | 154 (23) |
| ≤75% | 248 (8) | 103 (6) | 45 (10) | 90 (13) |
| Prior regimens | ||||
| 0 | 470 (16) | 288 (16) | 100 (22) | 82 (12) |
| 1 | 510 (17) | 380 (21) | 60 (13) | 70 (10) |
| 2 | 735 (25) | 480 (26) | 99 (22) | 156 (23) |
| 3 | 587 (20) | 368 (20) | 84 (18) | 135 (20) |
| ≥4 | 683 (23) | 328 (18) | 117 (26) | 238 (35) |
| Patient CMV serology-status* | ||||
| Positive | 1835 (61) | 1140 (62) | 286 (62) | 409 (60) |
| Negative | 1122 (38) | 690 (37) | 169 (37) | 263 (39) |
| Unknown | 28 (1) | 14 (1) | 5 (1) | 9 (1) |
| Stem cell source | ||||
| Marrow | 641 (21) | 527 (29) | 70 (15) | 44 (6) |
| PBMC | 2344 (79) | 1371 (71) | 390 (85) | 637 (94) |
| Donor | ||||
| Related | 1648 (55) | 1041 (56) | 238 (52) | 369 (54) |
| Unrelated | 1337 (45) | 803 (44) | 222 (48) | 312 (46) |
| GVHD prophylaxis regimen† | ||||
| CSP/MMF | 760 (25) | 95 (5) | 129 (28) | 536 (79) |
| CSP/MTX | 1066 (36) | 954 (52) | 89 (19) | 23 (3) |
| Tacrolimus-based | 480 (16) | 340 (18) | 68 (15) | 72 (11) |
| Triple drugs | 342 (11) | 280 (15) | 52 (11) | 10 (1) |
| Sirolimus-based | 147 (5) | 76 (4) | 70 (15) | 1 (<1) |
| Others | 38 (1) | 32 (2) | 5 (1) | 1 (<1) |
| Unknown | 152 (5) | 67 (4) | 47 (10) | 38 (6) |
| Diagnoses‡ | ||||
| Myeloid | 1802 (60) | 1241 (67) | 279 (61) | 282 (41) |
| Lymphoid | 1053 (35) | 566 (31) | 137 (30) | 348 (51) |
| Nonmalignant diseases | 130 (5) | 37 (2) | 42 (9) | 51 (8) |
| Disease risk for relapse§ | ||||
| High | 1797 (60) | 1025 (56) | 302 (66) | 470 (69) |
| Low | 1128 (38) | 789 (43) | 150 (33) | 189 (28) |
| Nonmalignant diseases | 60 (2) | 30 (2) | 8 (2) | 22 (3) |
MMF, mycophenolatemofetil; MTX, methotrexate. *CMV serology status was not known for 34 patients (1.1%).
GVHD prophylaxis regimen was not known for 156 (5%) of the total patient population.
Myeloid malignancies included acute myeloid leukemia, biphenotypic leukemia, chronic myeloid leukemia, and myelodysplastic syndromes; lymphoid/plasma cell malignancies included acute lymphocytic leukemia, chronic lymphocytic leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma, and plasma cell leukemia; and nonmalignant disease included aplastic anemia, sickle cell anemia, autoimmune disease, and other hematological nonmalignant diseases.
Low disease risk for relapse included acute leukemia in first complete remission; chronic myeloid leukemia in first chronic phase; myelodysplastic syndromes with refractory anemia or refractory anemia with ringed sideroblasts; chronic lymphocytic leukemia, lymphoma, or multiple myeloma in complete remission; and nonmalignant diseases. High disease risk for relapse included all other disease status.